Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Large Drop in Short Interest

Alzamend Neuro, Inc. (NASDAQ:ALZN) saw a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 62,900 shares, a decline of 52.7% from the November 30th total of 132,900 shares. Currently, 1.2% of the company’s shares are sold short. Based on an average daily trading volume, of 211,300 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets reduced their target price on shares of Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating on the stock in a research report on Monday, December 16th.

Alzamend Neuro Stock Down 3.2 %

Shares of NASDAQ ALZN opened at $1.20 on Friday. Alzamend Neuro has a twelve month low of $1.06 and a twelve month high of $15.06. The business has a fifty day simple moving average of $1.37 and a two-hundred day simple moving average of $2.39.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.